Literature DB >> 24334111

Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation.

Paul Muntner1, Monika M Safford, Mary Cushman, George Howard.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24334111     DOI： 10.1161/CIRCULATIONAHA.113.007648

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  18 in total

1.  Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Joseph Yeboah; Stefan Sillau; Joseph C Delaney; Michael J Blaha; Erin D Michos; Rebekah Young; Waqas T Qureshi; Robyn McClelland; Gregory L Burke; Bruce M Psaty; David M Herrington
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

Review 2.  Current drug treatment of hyperlipidemia in older adults.

Authors:  Dave L Dixon; Krista L Donohoe; Kelechi C Ogbonna; Sarah M Barden
Journal:  Drugs Aging       Date:  2015-02       Impact factor: 3.923

3.  Association Between Statin Use and Sex Hormone in the Multi-Ethnic Study of Atherosclerosis Cohort.

Authors:  Oludamilola W Oluleye; Richard A Kronmal; Aaron R Folsom; Dhananjay M Vaidya; Pamela Ouyang; Daniel A Duprez; Adrian S Dobs; Hirad Yarmohammadi; Suma H Konety
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

4.  Personalized Statin Therapy and Coronary Atherosclerotic Plaque Burden in Asymptomatic Low/Intermediate-Risk Individuals.

Authors:  Ranganath Muniyappa; Radwa A Noureldin; Khaled Z Abd-Elmoniem; Riham H El Khouli; Jatin Raj Matta; Ahmed Hamimi; Siri Ranganath; Colleen Hadigan; Lynnette K Nieman; Ahmed M Gharib
Journal:  Cardiorenal Med       Date:  2018-03-26       Impact factor: 2.041

5.  Adult Height, Prevalent Coronary Artery Calcium Score, and Incident Cardiovascular Disease Outcomes in a Multiethnic Cohort.

Authors:  Joseph Yeboah; Michael J Blaha; Erin D Michos; Waqas Qureshi; Michael Miedema; Peter Flueckiger; Carlos J Rodriguez; Moyses Szklo; Alain G Bertoni
Journal:  Am J Epidemiol       Date:  2017-10-15       Impact factor: 4.897

6.  Changes in erectile dysfunction over time in relation to Framingham cardiovascular risk in the Boston Area Community Health (BACH) Survey.

Authors:  Shona C Fang; Raymond C Rosen; Joseph A Vita; Peter Ganz; Varant Kupelian
Journal:  J Sex Med       Date:  2014-10-08       Impact factor: 3.802

7.  Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.

Authors:  Joseph Yeboah; Tamar S Polonsky; Rebekah Young; Robyn L McClelland; Joseph C Delaney; Farah Dawood; Michael J Blaha; Michael D Miedema; Christopher T Sibley; J Jeffrey Carr; Gregory L Burke; David C Goff; Bruce M Psaty; Philip Greenland; David M Herrington
Journal:  Circulation       Date:  2015-07-29       Impact factor: 29.690

8.  Assessing the performance of the Framingham Stroke Risk Score in the reasons for geographic and racial differences in stroke cohort.

Authors:  Leslie A McClure; Dawn O Kleindorfer; Brett M Kissela; Mary Cushman; Elsayed Z Soliman; George Howard
Journal:  Stroke       Date:  2014-04-15       Impact factor: 7.914

9.  Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study.

Authors:  Nancy R Cook; Paul M Ridker
Journal:  JAMA Intern Med       Date:  2014-12       Impact factor: 21.873

10.  2013 ACC/AHA versus 2004 NECP ATP III Guidelines in the Assignment of Statin Treatment in a Korean Population with Subclinical Coronary Atherosclerosis.

Authors:  Chang Hee Jung; Min Jung Lee; Yu Mi Kang; Dong Hyun Yang; Joon-Won Kang; Eun Hee Kim; Duk-Woo Park; Joong-Yeol Park; Hong-Kyu Kim; Woo Je Lee
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.